Status:
COMPLETED
Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects
Lead Sponsor:
NGM Biopharmaceuticals, Inc
Conditions:
Cachexia
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects
Eligibility Criteria
Inclusion
- Normal ECG findings
Exclusion
- Significant history or clinical manifestation of any allergic, dermatological, hepatic, renal, hematological, pulmonary, metabolic, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
Key Trial Info
Start Date :
January 29 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 11 2019
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT03392116
Start Date
January 29 2018
End Date
March 11 2019
Last Update
August 20 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nucleus Network Limited
Melbourne, Australia